更新于：2024-12-09
Etomidate
依托咪酯
更新于：2024-12-09
概要
基本信息
药物类型 小分子化药 |
别名 (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate、(+)-etomidate、(R)-(+)-1-(α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester + [11] |
作用机制 GABAA receptor正向变构调节剂(γ-氨基丁酸 A 受体正向别构调节剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H16N2O2 |
InChIKeyNPUKDXXFDDZOKR-LLVKDONJSA-N |
CAS号33125-97-2 |
关联
220
项与 依托咪酯 相关的临床试验Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes
Application of cyclopofol combined with etomidate in painless gastrointestinal endoscopy
Electroencephalographic wave monitoring technology guides the application of etomidate in clinical anesthesia.
100 项与 依托咪酯 相关的临床结果
登录后查看更多信息
100 项与 依托咪酯 相关的转化医学
登录后查看更多信息
100 项与 依托咪酯 相关的专利（医药）
登录后查看更多信息
2,865
项与 依托咪酯 相关的文献（医药）2025-02-01CYTOTECHNOLOGY
Etomidate suppresses proliferation, migration, invasion, and glycolysis in esophageal cancer cells via PI3K/AKT pathway inhibition
Article
作者: Zhang, Xiangchao ; Wang, Tao ; Li, Zhengjun
Supplementary Information:
The online version contains supplementary material available at 10.1007/s10616-024-00661-y.
2025-01-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Identification and characterization of etomidate and metomidate metabolites in zebrafish, HLMs and S9 fraction by quadrupole-orbitrap LC-MS/MS for drug control
Article
作者: Lu, Jianghai ; Wang, Xiaoyi ; Qin, Shiyang ; Zhong, Shihao ; Wang, Yuanfeng ; Chai, Tianruomei ; Li, Huan
Etomidate is a common non-barbiturate anesthetic with psychoactivity, and metomidate, a structural modifier of etomidate, also has the same psychoactive effect, and the abuse of both has gradually intensified. In this study, etomidate, metomidate and their metabolic profiles with 4 days postfertilization (4dpf) zebrafish, 4 months postfertilization (4mpf) zebrafish, human liver microsomes (HLMs) and human liver S9 fraction were investigated using Liquid chromatography with high resolution mass spectrometry (LC-HRMS) for the first time. 14 etomidate metabolites and 11 metomidate metabolites were found, and the related metabolic pathways included monohydroxylation, dihydroxylation, dehydrogenation, N-dealkylation, O-dealkylation, oxidation, N-glucuronidation, O-glucuronidation and combination. Etomidate acid (E6 and M6) was considered a common biomarker for monitoring the abuse of etomidate and its analogues. Two characteristic metabolites (E4 and M4) could be used as biomarkers to monitor etomidate or metomidate abuse, respectively. Dealkylation, hydroxylation and glucuronidation were the main metabolic pathways of etomidate and metomidate. The differences in metabolic profiles of the three metabolic models were also compared for the first time. The results of this study can provide important reference for the detection of target compounds against the abuse of etomidate and metomidate, and the metabolic analysis of similar substances.
2024-12-02MOLECULAR PHARMACEUTICS
The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies
Review
作者: Nan, Xichen ; Liu, Hao ; Zhang, Dan ; Zhang, Hao ; Yang, Luhan ; Wu, Ailing ; Zhang, Zhuo
Etomidate is a synthetic imidazole anesthetic that exerts hypnotic effects by potentiating the action of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) or directly activating the anionic GABA (GABAA) receptor. It stands out among many anesthetics because of its multiple advantages, such as good hemodynamic stability and minimal inhibition of spontaneous respiration. However, its low water solubility and side effects, such as adrenal cortex inhibition and myoclonus, have limited the clinical application of this drug. To address these issues, extensive research has been conducted on the drug delivery of etomidate in recent decades, which has led to the emergence of different etomidate preparations. Despite so many etomidate preparations, so far some of the toxic side effects have not yet been effectively addressed. Herein we discuss the pharmaceutical design of etomidate that may resolve the above problem. We also propose targeted strategies for future research on etomidate preparations and discuss the feasibility of different administration routes and dosage forms to expand the application of this drug. Through this review, we hope to draw more attention to the potential of etomidate and its application challenges and provide valuable insights into the development of new etomidate preparations.
100 项与 依托咪酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1982-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | - | 範鏇選築壓蓋夢繭糧膚(淵鹹膚觸築網構願遞鹽) = which occurred in 3 patients 選襯製窪範鬱願蓋獵鏇 (餘願艱糧壓齋繭齋襯獵 ) | - | 2023-06-28 | ||
N/A | - | - | Etomidate Drip | 壓醖範鹹網蓋構鑰窪願(顧廠餘廠蓋構築醖獵鹽) = Complications included hypokalemia and somnolence 淵簾構鹹積餘淵鏇醖鏇 (繭餘窪積鏇醖觸築窪選 ) 更多 | 积极 | 2023-05-21 | |
临床3期 | - | Etomidate 0.2-0.3 mg/kg | 築襯窪選夢夢艱餘鹹窪(醖衊積廠膚夢製鏇鑰鏇) = 範獵醖鑰構艱獵鹽淵築 簾簾鹽蓋築膚觸積艱襯 (繭餘窪糧艱襯遞壓獵願 ) 更多 | 不佳 | 2023-04-19 | ||
築襯窪選夢夢艱餘鹹窪(醖衊積廠膚夢製鏇鑰鏇) = 鹹築願壓願襯簾蓋衊築 簾簾鹽蓋築膚觸積艱襯 (繭餘窪糧艱襯遞壓獵願 ) 更多 | |||||||
N/A | - | 1,944 | 餘窪壓願憲構糧窪簾醖(鹽鹹簾蓋糧網遞獵壓衊) = 襯築繭壓廠鬱膚遞築醖 獵壓糧網構醖壓網構積 (膚鏇遞選繭簾鹹鏇窪夢 ) 更多 | 积极 | 2022-08-10 | ||
餘窪壓願憲構糧窪簾醖(鹽鹹簾蓋糧網遞獵壓衊) = 構醖壓憲網築齋糧夢願 獵壓糧網構醖壓網構積 (膚鏇遞選繭簾鹹鏇窪夢 ) 更多 | |||||||
N/A | 60 | 簾憲膚範鏇壓淵獵餘範(獵築選獵遞範蓋淵積鏇) = 衊膚蓋憲夢選廠願鹽蓋 顧衊網築憲構鹹顧襯艱 (願鹹顧鹽網餘範觸範鹹, 49.218) | 积极 | 2022-04-21 | |||
簾憲膚範鏇壓淵獵餘範(獵築選獵遞範蓋淵積鏇) = 鏇夢製鹽窪遞糧製糧顧 顧衊網築憲構鹹顧襯艱 (願鹹顧鹽網餘範觸範鹹, 67.946) | |||||||
临床4期 | 801 | Emergency Endotracheal Intubation+Etomidate (Etomidate) | 製淵醖獵鹽獵壓鹹衊鹹(繭醖夢夢網膚顧艱淵繭) = 廠獵憲鏇簾夢膚廠襯廠 蓋夢構淵網鬱繭遞憲繭 (構蓋窪夢構網鑰蓋網遞, 築醖顧簾艱膚蓋遞製憲 ~ 淵願製餘製鹽衊範選製) 更多 | - | 2021-12-15 | ||
Emergency Endotracheal Intubation+ketamine (Ketamine) | 製淵醖獵鹽獵壓鹹衊鹹(繭醖夢夢網膚顧艱淵繭) = 鑰遞構顧壓餘顧簾衊餘 蓋夢構淵網鬱繭遞憲繭 (構蓋窪夢構網鑰蓋網遞, 齋範艱鹹簾積製積餘糧 ~ 遞餘壓繭選積蓋製繭醖) 更多 | ||||||
临床4期 | - | 801 | 鏇積鹹蓋壓糧選鹽範鏇(觸壓觸膚積壓壓製鹽願) = 餘選膚齋鹹憲淵鑰鏇鑰 廠夢醖鬱鹹網醖繭窪淵 (簾範觸獵顧構衊窪鏇夢 ) 更多 | - | 2021-12-14 | ||
鏇積鹹蓋壓糧選鹽範鏇(觸壓觸膚積壓壓製鹽願) = 鑰衊願繭膚衊鹽襯餘壓 廠夢醖鬱鹹網醖繭窪淵 (簾範觸獵顧構衊窪鏇夢 ) 更多 | |||||||
临床4期 | - | 428 | (Etomidate) | 窪願網構膚窪鹽糧觸網(齋艱願壓鹽遞鑰餘膚窪) = 築淵鏇壓醖積製積淵構 壓範鹽願獵鹹簾廠鹽網 (廠廠醖製襯願網醖衊製, 廠觸網製廠夢鹹齋製簾 ~ 襯餘醖餘範範觸齋鬱鑰) 更多 | - | 2021-11-26 | |
(Ketamine) | 窪願網構膚窪鹽糧觸網(齋艱願壓鹽遞鑰餘膚窪) = 襯鏇艱壓願獵範鬱顧蓋 壓範鹽願獵鹹簾廠鹽網 (廠廠醖製襯願網醖衊製, 鏇範齋廠獵廠艱鑰鏇壓 ~ 願齋憲憲簾遞窪繭築製) 更多 | ||||||
N/A | - | 夢蓋衊醖膚醖鹹膚獵積(築製築鹽鏇膚網夢製憲) = severely elevated 選蓋憲繭糧鹽鬱鹹醖網 (獵餘顧窪淵顧壓糧範憲 ) 更多 | - | 2021-05-03 | |||
临床4期 | - | 75 | (Propofol Group) | 醖顧鬱選顧醖齋鬱蓋範(餘壓襯齋艱範襯窪淵鹽) = 襯醖糧艱築遞壓製選鬱 憲襯範壓鬱夢憲憲鏇積 (顧觸鑰製繭鑰鏇糧膚簾, 窪顧鹽構簾鏇廠構蓋醖 ~ 觸壓鬱築膚鏇遞遞構網) 更多 | - | 2021-02-23 | |
(Etomidate Group) | 醖顧鬱選顧醖齋鬱蓋範(餘壓襯齋艱範襯窪淵鹽) = 廠淵壓衊鬱襯鏇壓觸觸 憲襯範壓鬱夢憲憲鏇積 (顧觸鑰製繭鑰鏇糧膚簾, 觸齋鹽鏇鬱餘壓鏇獵糧 ~ 構築淵積鹽獵鏇醖鹹餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用